ABUS vs WELL · P/E 5.4, rev $6.2M vs P/E 100, rev $10.84B
Arbutus Biopharma Corp (ABUS) versus Welltower Inc (WELL) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Welltower Inc (WELL) is a reit - healthcare facilities company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported WELL revenue for 2025-12-31 was $10.84B. Net income was $936.8M. Revenue was up 35.6% from 2024-12-31 to 2025-12-31. WELL currently screens at market cap $145.81B and trailing P/E 99.8.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. WELL currently screens at market cap $145.81B and trailing P/E 99.8.
Not investment advice. Open the ABUS and WELL stock pages for the full models.
Not investment advice.